IP Library Granted Patent US 10,662,428
Granted Patent B2
US 10,662,428 · App. 16/381,288 · Granted May 26, 2020

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Inventors: Leonid Beigelman (San Mateo, CA); James McSwiggen (Arlington, MA); Chandra Vargeese (Schwenksville, PA)
Assignee: SIRNA THERAPEUTICS, INC.
C12N15/113C07H21/02C12N15/111C12N15/1131C12N15/1137C12N15/1138C12N15/8218C12Y304/21021C12N2310/14C12N2310/141C12N2310/315C12N2310/317C12N2310/322C12N2310/3231C12N2310/344C12N2310/346C12N2310/351C12N2310/53C12N2320/32C12N2320/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,428
App. No.
16/381,288
Granted
May 26, 2020
Kind
B2
Abstract

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.

Claims (11)

1. A double-stranded short interfering nucleic acid (siNA) molecule comprising a sense strand and an antisense strand, wherein:

a) the antisense strand is complementary to the nucleotide sequence of SEQ ID NO: 449;

b) each strand of said double-stranded siNA molecule is 21 nucleotides in length;

c) all 21 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule;

(d) the sense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides;

(e) the antisense strand comprises 10 or more 2′-deoxy, 2′-O-methyl, 2′-deoxy-2′-fluoro, or universal base modified nucleotides; and

(f) 10 or more pyrimidine nucleotides of the sense and/or antisense strand are 2′-deoxy, 2′-O-methyl or 2′-deoxy-2′-fluoro nucleotides; and

wherein the siNA molecule downregulates expression of a Hepatitis B virus target gene.

2. The siNA molecule of claim 1 , wherein said antisense strand comprises a phosphorothioate internucleotide linkage at the 3′ end of said antisense strand.

3. The siNA molecule of claim 1 , which comprises no ribonucleotides.

4. A pharmaceutical composition comprising the siNA molecule of claim 1 in an acceptable carrier or diluent.

Assignments (4)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2019
From: VARGEESE, CHANDRA
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 050117/0641 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2019
From: BEIGELMAN, LEONID; MCSWIGGEN, JAMES
To: MERCK SHARP & DOHME CORP.
Reel/Frame 050117/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2019
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 050117/0735 →
Continuity (22)
Continuation 15977746 · May 11, 2018
Continuation 15637579 · Jun 29, 2017
Continuation 15084865 · Mar 30, 2016
Continuation 14861805 · Sep 22, 2015
Continuation 14514112 · Oct 14, 2014
Continuation 14083525 · Nov 19, 2013
Continuation 13480655 · May 25, 2012
Continuation 10720448 · Nov 24, 2003
Continuation In Part 10693059 · Oct 23, 2003
Continuation In Part 10652791 · Aug 29, 2003
Continuation In Part 10444853 · May 23, 2003
Continuation In Part PCTUS0305346 · Feb 20, 2003
Continuation In Part PCTUS0305028 · Feb 20, 2003
Continuation In Part 10427160 · Apr 30, 2003
Provisional Application 60440129 · Jan 15, 2003
Provisional Application 60409293 · Sep 9, 2002
Provisional Application 60408378 · Sep 5, 2002
Provisional Application 60406784 · Aug 29, 2002
Provisional Application 60386782 · Jun 6, 2002
Provisional Application 60363124 · Mar 11, 2002
Provisional Application 60358580 · Feb 20, 2002
Related Publication 20190233821A1 · Aug 1, 2019